Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Motor Activity 22Breast Neoplasms 14Neoplasms 9Fatigue 5Prostatic Neoplasms 4Obesity 4Pancreatic Neoplasms 3Colorectal Neoplasms 3Peripheral Nervous System Diseases 2Overweight 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Cognitive Dysfunction 2Cardiovascular Diseases 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Smoking 1Skin Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ovarian Neoplasms 1Osteolysis 1Non-alcoholic Fatty Liver Disease 1Neuroectodermal Tumors, Primitive 1Neurocognitive Disorders 1Multiple Endocrine Neoplasia Type 1 1Metabolic Syndrome 1

Interventions

Vincristine 2Radiotherapy 2Cyclophosphamide 2Cisplatin 2Pemetrexed 1Maintenance Chemotherapy 1Lomustine 1Induction Chemotherapy 1HhAntag691 1Gemcitabine 1Exercise 1Diploidy 1Craniospinal Irradiation 1Carboplatin 1CLR1404 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroectodermal Tumors, Primitive × Exercise × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡